SECOND AMENDED AND RESTATED FINANCIAL AND INVESTOR RELATIONS AGREEMENT This Agreement is dated effective as of January 28, 2011.Financial and Investor Relations Agreement • October 3rd, 2011 • ACM Alpha Consulting Management AG • Pharmaceutical preparations • Ontario
WHEREAS Helix previously retained ACM to provide Helix with investor and financial advisory services in Europe, by execution of the Financial and Investor Relations Agreement dated as of January 25, 2010 (hereinafter referred to as the “Original Agreement”);
JOINT FILING AGREEMENTJoint Filing Agreement • October 3rd, 2011 • ACM Alpha Consulting Management AG • Pharmaceutical preparations
The undersigned hereby agree that the Statement on Schedule 13D with respect to the common shares of Helix BioPharma Corp., dated as of October 3, 2011, is, and any further amendments thereto (including amendments on Schedule 13D or Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the United States Securities Exchange Act of 1934 and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this joint filing agreement this 3rd day of October, 2011.
